Cambia Health Solutions is a nonprofit total health solutions company based in the Pacific Northwest/Intermountain region, serving consumers and communities for nearly 100 years. Cambia companies provide a wide range of products and services, including healthcare information technology and software development, retail healthcare, health insurance plans that carry the Blue Cross and Blue Shield brand, life insurance, pharmacy benefit management, consumer engagement and wellness.

Cambia Health Solutions

Mitsui & Co is a general trading company. Mitsui & Co's business area covers energy, machinery, chemicals, food, textile, logistics, finance, and more.  They will contribute to address diverse industrial needs, through procurement, supply and sales of iron and steel products and investment to processing and distribution businesses in Japan and abroad.  Through business development, investment and trading of mineral, metal resources and metals, they reinforce a stable supply of the resources and materials necessary for both industry and society. They are also active in metal recycling and other initiatives to develop industrial solutions to environmental issues.  They contribute to creating better lives through the long-term, reliable supply of social infrastructure such as electricity, gas, water,railways and other logistics infrastructure. They provide sales, financing, lease, transportation and logistics, and project investment in a wide range of machineries, including large-scale plants, marine resource development facilities,ships, and aerospace, motor vehicles, construction/mining machinery and industrial machinery.  Their chemicals business encompasses trade and investment in a range of industries, from upstream chemicals such as basic chemicals, fertilizer resources, through to downstream chemicals such as functional materials, electronics materials,fertilizers,aguricultural chemicals and specialty chemicals. They are also pursuing new initiatives such as green chemicals.  Through upstream development, logistics and trading of energy resources such as oil, natural gas/LNG ,coal and uranium, they contribute to the stable supply of energy vital to both industry and society. As part of efforts to achieve a low-carbon society, they are also actively involved in next-generation energy and environemental businesses.   Adapting to changes in consumption and lifestyles while meeting consumers’ diverse needs, they provide value-added products and services, develop businesses and make investments in the fields of food resources, food products, retail support business, medical and healthcare, fashion, forestry plantation resources, real estate-related business.  Through their ICT, Finance and Logistics business, they work on a diverse range of projects aimed at developing innovative business and expanding their business field. At the same time, they aim to strengthen their company-wide earnings base by pursuing strategic projects and new opportunities and providing specialized functions that contribute to the whole Mitsui & Co. group.  Trading in various commodities led by overseas trading subisidiaries of offices located in the Americas area. Trading in various commodites led by overseas trading subsidiaries or offices located in Europe, the Middle East and Africa area. Trading in various commodities led by overseas trading subsidiaries of offices located in the Asia Pacific area.

Mitsui & Co

Heritage Provider Network (HPN) is a limited Knox-Keene licensed organization in California that provides affordable quality care to its members. Through innovative programs and services designed specifically for the managed care environment, HPN and its medical groups have been successful in delivering the goals it set out to achieve while establishing long-standing, favorable provider relationships.

Heritage Provider Network

Alexandria Real Estate Equities is a real estate company. They offer engineering, asset management, laboratory operations, life science, construction, planning, health and environment, safety, project management, finance, collaboration, accounting, communications and public relations, events, venture investment, and sustainability.

Alexandria Real Estate Equities

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options.   There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma.   In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.

Celgene

Gi Global Health Fund LP

Cigna Ventures is the arm venture of Cigna, that accelerate growth of start ups in health care industry. The company's mission is to accelerate Cigna’s ability to improve the health, well-being and sense of security of the people we serve by partnering with and investing in innovative companies, and delivering differentiated value in the marketplace. It focuses on harnessing transformative ideas in insights and analytics; digital health and retail; and care delivery and management.

Cigna Ventures

Amgen Ventures is a venture capital investment arm of Amgen Inc. specializing in investments in early and later stage companies. The firm primarily invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, and cardiovascular therapeutics. In oncology and hematology it focuses on novel therapeutics including signal transduction, cell cycle, and apoptosis; hematopoiesis including anemia, neutropenia, and stem cell mobilization; and supportive care including mucositis and cachexia. In nephrology the firm focuses on renal failure and hyperparathyroidism. For inflammation the firm focuses on rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, asthma and COPD, and osteoarthritis. Under cardiovascular, it focuses on acute coronary syndromes, dyslipidemia, and heart failure and under metabolic disorders it focuses on diabetes, metabolic syndrome, and osteoporosis. The focus on neuroscience included pain including neuropathic and inflammatory, alzheimer's disease, parkinson's disease, sleep disorder, cognition, and schizophrenia. In discovery research and technology the firm focuses on early-stage drug discovery collaborations, innovative chemical entity collections, diagnostics and biomarkers, novel antibody platforms, assay biologicals and devices, and target-focused structural biology and computational tools. It primarily invests in the North America, Europe, and the United Kingdom. The firm typically invests between $2 million and $3 million per transaction and may invest up to $10 million per company. It prefers to have an ownership stake of less than 15 % in its portfolio companies. Amgen Ventures was founded in 2004 and is based in San Francisco, California with additional offices in Seattle, Washington; Thousand Oaks, California; and Cambridge, Massachusetts.

Amgen Ventures

Echo Health Ventures is a venture capital firm that focuses on investing in health care companies. From offices in Durham, Portland, and Seattle, Echo Health Ventures invests in health care companies. They work with portfolio companies to accelerate their innovations to scale nationally. As stage-agnostic investors, they are committed to a new approach to strategic investing – an approach that brings more than capital to the table, an approach focused on developing deep, high-value relationships with their portfolio companies.

Echo Health Ventures

Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that are developing transformative new modalities and platforms to meaningfully improve human health.

Alexandria Venture Investments

Aitia

Aitia is the leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs. By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden biological mechanisms of disease to create Digital Twins of disease in oncology, neurodegenerative disorders, and immunology. Gemini Digital Twins are being used today to discover novel therapies and accelerate R&D in multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with several more in development. Aitia’s partners include seven of the top ten pharmaceutical companies, leading academic research and medical centers, medical societies, leading multi-omic data companies, and patient advocacy groups globally.

Aitia is an AI-enabled biotechnology company that utilizes causal AI and Gemini Digital Twins to discover and develop new drugs in neurodegenerative diseases and oncology. The company's technology combines multi-omic patient data, high-performance computing, and causal AI to create virtual models of diseases. These Gemini Digital Twins are reverse-engineered from genetic, multi-omic, and clinical data from patients to reveal how genes, proteins, and molecules interact within cells and tissues to drive clinical outcomes. The platform enables researchers to rapidly test billions of experiments, such as gene and protein knockdowns or drug candidate applications, in a human patient context rather than using traditional animal models or cell cultures.

Servier and Aitia Announce a New Collaboration Focused on Parkinson’s Disease

Aitia Expand Collaboration with Servier to Discover and Develop New Drugs for Brain Cancer Using AI-Driven Digital Twins

Orion and Aitia Enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology

Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology

Aitia Enters into Multi-Year AI-Driven Drug Discovery and Drug Simulation Collaboration with Servier for Pancreatic Cancer

Discovering Next Generation Drugs with Gemini Digital Twins

Using real-time data to create dynamic virtual representations of the real world

Digital Twin

Orion to use Aitia’s ‘digital twins’ to identity potential new cancer drugs

Servier Pharmaceuticals

To develop new drug treatments for gliomas using AI-driven digital twins technology, combining Aitia's Gemini DT and Servier's therapeutic expertise in oncology.

Companies that offer digital twins to assess risks and recommend solutions in areas such as disaster management, DNA testing, clinical trials (to simulate effects of treatments), etc.

Servier

To leverage Aitia's Gemini Digital Twins and Servier's oncological expertise to explore novel drug targets and develop potential treatments for gliomas, a type of brain cancer. The partnership, initiated in 2022 for multiple myeloma, has expanded to include pancreatic cancer and Parkinson's disease.

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

Biotechnology companies that have integrated AI as a core component of their in-house drug development process. They typically have a few in-house drug development programs, and also collaborate with pharma companies to develop certain drugs.

Aitia is an AI-enabled biotechnology company that utilizes causal AI and Gemini Digital Twins to discover and develop new drugs in neurodegenerative diseases and oncology. The company's technology combines multi-omic patient data, high-performance computing, and causal AI to create virtual models of diseases. These Gemini Digital Twins are reverse-engineered from genetic, multi-omic, and clinical data from patients to reveal how genes, proteins, and molecules interact within cells and tissues to drive clinical outcomes. The platform enables researchers to rapidly test billions of experiments, such as gene and protein knockdowns or drug candidate applications, in a human patient context rather than using traditional animal models or cell cultures.
The company's approach centers on two key innovations: causal AI, which identifies genetic and molecular changes driving diseases and patient responses to therapies, and Gemini Digital Twins, which allow for high-throughput virtual experiments to discover drug candidates with higher potential for clinical trial success. Aitia's technology has been deployed across multiple therapeutic areas including oncology, neurodegeneration, cardiometabolic disorders, and immunology.
Key customers and partnerships
Aitia has established several strategic partnerships with major pharmaceutical companies. The company expanded its collaboration with Servier in October 2024 to tackle gliomas, marking their fourth research area partnership since 2022, which includes programs in Multiple Myeloma, pancreatic cancer, and Parkinson's disease. In September 2024, Aitia entered into a partnership with Orion Corporation for cancer drug discovery. The company also formed a strategic agreement with Charles River Laboratories in November 2023 for neurodegenerative diseases and oncology research, which included the co-development of patient-derived xenograft Digital Twins for oncology research.

Norway-based Cognite is a provider of digital twin modeling software for an entire operation through complex industrial data. With machine learning and physics simulators, companies are able to use these for predictive maintenance, production optimization, and better decision-making.&nbsp;Its main solution Cognite Data Fusion offers an open industrial digital twin by integrating IT, operational, and engineering data from sources such as ERPs, MES, and IoT platforms. The data is cleaned and contextualized into a single location and turned into insights for actionable advice, which then is used to build and automate workflows. The company claimed to be the first company to <a href="https://sp-edge.com/updates/17445">achieve DNV-RP-A204 compliance </a>for its core product, Cognite Data Fusion.&nbsp;In <a href="https://sp-edge.com/updates/16217">February 2023</a>, the company advanced with new data-modeling capabilities to accelerate (up to 10–25x) deployments of industrial digital solutions and reduce cost and complexity for users. In <a href="https://sp-edge.com/updates/25399">January 2024</a>, the company launched the beta version of a GenAI remote operations control room at the Celanese facility to deliver real-time operational transparency.&nbsp;Key customers and partnershipsThe company provides its solution mainly to the oil and gas, power and utilities, and manufacturing sectors. Its key customers include Siemens and Rockwell Automation.&nbsp;The company had partnered with Microsoft in January 2024 to integrate Cognite Data Fusion with Microsoft Fabric and deliver an AI-powered industrial data operations solution. In June 2022, Cognite formed a joint venture, CNTXT, with Saudi Aramco to provide its digitization services in the Middle East region for the private and public sectors. Also, in October 2022, the company partnered with industrial automation company Rockwell Automation to develop an industrial data hub for the manufacturing sector by combining Rockwell’s software, FactoryTalk, and Cognite Data Fusion.Furthermore, in September 2022, the company partnered with Schlumberger to integrate Cognite Data Fusion to Schlumberger’s Enterprise Data Solution to contextualize data in an interoperable platform.&nbsp;Funding and financialsThe company raised USD 150 million in May 2021 in an equity funding round from TCV, which brought the valuation of the company to USD 1.6 billion. The funds were allocated toward expanding its platform to global industries.&nbsp;Furthermore, in January 2022, petroleum and gas company Saudi Aramco purchased 100% of Aker BP's shares in Cognite to own a majority stake of 7.4% at a value of USD 183 million.

Cognite

Nexar develops AI-powered connected dash cameras and software solutions for vehicles. The company's dash cameras record high-definition video footage of both the exterior and interior of vehicles, with models offering resolutions ranging from 1080p to 4K. Its products feature automatic incident detection, GPS tracking, parking mode surveillance, and cloud backup capabilities. The cameras connect to smartphones via WiFi and utilize an AI-powered mobile app that automatically saves important clips and allows users to access footage remotely. Nexar's product lineup includes several models like the Nexar One (featuring 4K resolution and LTE connectivity), Nexar Beam (a compact single-lens camera), and Nexar Pro (a dual-lens system for interior/exterior recording). The cameras use AI algorithms to detect collisions, hard braking events, and other incidents, automatically generating detailed reports with video evidence, location data, and speed information for insurance claims.
Key customers and partnerships
The company primarily serves individual drivers, ride-share operators, and commercial fleet operators. Nexar's technology particularly appealed to professional drivers, ride-share services like Uber and Lyft, and fleet management companies looking to monitor driver behavior and vehicle security remotely. The company also caters to parents monitoring teen drivers through its real-time alert and tracking capabilities.

Nexar

Seeq is a provider of data analytics enabling insights, predictions, and collaboration for better production and business outcomes.The company’s product portfolio includes software for data analytics including 1) Seeq Workbench for advanced analytics, 2) Seeq Organizer for publishing reports and dashboards, 3) Seeq Data Lab for accessing Python libraries, and 4) Seeq Cortex for IT governance, data connectivity, and calculation features. Furthermore, the company provides deployment via cloud, SaaS solutions, and on premise depending on the customer’s system.Key customers and partnershipsThe company provides its services in more than 40 countries focusing on process manufacturing industries, including oil and gas, pharmaceutical, chemical, energy, mining, and food and beverage. In June 2024, Seeq partnered with Equinor, an international energy company, to leverage Seeq's platform across Equinor's global assets.Seeq’s software is built on long-term vendor partnerships such as SIsoft, Honeywell (since 2017), and Siemens (since 2017). Seeq has also partnered with Amazon Web Services (AWS) and Microsoft Azure to develop features specific to their offerings, recognizing Seeq's expertise in providing cloud solutions for the manufacturing and industrial sector. Other partners include Schneider Electric and Inductive Automation.

Seeq

Q Bio provides a predictive assessment platform to analyze existential risk in an individual’s health. The company claims its platform, Gemini Digital Twin, is the fastest and safest scanner, and taking 15 minutes to scan the entire body.The company provides the Q Exam, which gathers millions of data points from the individual’s body, such as blood, saliva, and vitals, and sends results via a web-based Q Dashboard to the individual’s physicians. Data is facilitated via the Gemini platform that captures whole body patient vitals in a non-invasive manner.&nbsp;&nbsp;The company operates a B2B2C business model offering services via employers and to individuals. It charges membership plans for one year at USD 3,495 for one exam and USD 6,495 for two exams.&nbsp;Q Bio's is developing the Mark I scanner which uses proprietary tensor field mapping technology to offer full-body scans with 3,000 anatomical measurements in just 10 minutes, creating digital twins and large biological models for health insights. In <a href="https://sp-edge.com/updates/31878">July 2024</a>, Q Bio secured USD 27 million in strategic funding to propel the Mark I scanner toward market launch.&nbsp;Key customers and partnershipsIn May 2021, the company partnered with Amazon Web Services to provide Q Bio’s services on its cloud platform.

Q Bio

Israel-based Locusview has developed a digital construction management platform to allow companies to manage projects from start to end. The platform is supported by technological capabilities in physical assets, such as plastic and steel pipes, to enable a digital thread (information of an asset such as model or size) and for supply chain and asset traceability.&nbsp;The platform provides features to manage construction projects in and off the field including GPS and sensor-based data collection, fieldwork validations, cloud-based deployment and scaling, real-time progress tracking, online approvals, and built-in reports. Furthermore, companies can lease the complete solution or get a consultation for a customized solution.The company operates a B2B business model, providing its services mainly to the energy, utilities, and telecom industries.&nbsp;Key customers and partnershipsThe company’s customer base includes more than 30 leading energy utilities and telecom companies. The company has a market presence in India, the US, Australia, Mexico, the UK, and Israel.&nbsp;The company had partnered with Esri to offer a complete end-to-end solution for Esri-based utilities. &nbsp;&nbsp;&nbsp;Funding and financialsThe company raised USD 64 million in April 2021 in a Series A funding round led by Israel Growth Partners. The funds were used to expand the platform capabilities and for market expansion.

Locusview

Companies that facilitate the creation of digital twins to monitor and maintain assets, including buildings and network infrastructure.

Platforms that facilitate digital twin modeling by either collectively or individually offering any combination of data capture and analytics solutions.

Companies that offer digital twins to gain insights for use in commercial planning, logistics and distribution, and other supply chain processes.

Companies that offer digital twins to design and build components contributing to smart cities, roads, airports, public transportation systems, etc.

Startups can create digital twins of cities; enables modeling/simulation to improve efficiency/quality of life

Startups can use digital twins to automate and proactively monitor industrial production lines and facilities

Digital twins are the primary enabling technology for the digital twin industry

PROMINENT_CATEGORY

<div>

 AI-biotech firm Aitia and pharmaceutical company Servier have broadened their collaboration, shifting their attention to brain cancer, specifically gliomas. Utilizing Aitia's Gemini Digital Twins and Servier's oncological knowledge, they aim to leverage patient data to seek new drug targets and develop treatments for gliomas. The partnership began in 2022 with drug discovery for multiple myeloma, and later expanded to include pancreatic cancer and Parkinson's disease by January 2024.
 Aitia, previously known as GNS Healthcare, is renowned for its application of causal AI and digital twins technology in expediting drug discovery. They use their exclusive Gemini Digital Twins platform to model diseases, with an aim of revealing hidden biological processes in areas such as oncology, neurodegeneration, and immunology. Aitia rebranded in January 2023, shifting from a general AI approach to a more concentrated focus on drug discovery.
 
</div>

Aitia

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless